US equities
|
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Harmony Biosciences
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Today 8:05 EDT
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
September 03, 2026
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
August 27, 2026
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
August 06, 2026
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
August 04, 2026
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
July 21, 2026
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences to Participate in Upcoming Investor Conferences
November 18, 2025
From
Harmony Biosciences
Via
Business Wire
Tickers
HRMY
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
July 15, 2025
From
Harmony Biosciences
Via
Business Wire
Tickers
HRMY
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
January 13, 2025
From
Harmony Biosciences
Via
Business Wire
Tickers
HRMY
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
August 06, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
October 31, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 01, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 02, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 21, 2023
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 01, 2022
From
Harmony Biosciences
Via
GlobeNewswire
Tickers
HRMY
